This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • Bausch Health and Clearside Biomedical announce FD...

Bausch Health and Clearside Biomedical announce FDA re-filing acceptance for Xipere to treat macular edema associated with uveitis.

Read time: 1 mins
Published:3rd Jun 2021
Bausch Health Companies Inc. and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. announced that the FDA has accepted the re-submitted New Drug Application for Xipere (triamcinolone acetonide suprachoroidal injectable suspension).

FDA determined that the filing is a Class 2 resubmission and therefore assigned a Prescription Drug User Fee Act (PDUFA) action date of October 30, 2021. Xipere is an investigational therapy with a proposed indication of treatment of macular edema associated with uveitis. Xipere is designed for suprachoroidal administration via Clearside's patented, proprietary SCS Microinjector that offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The SCS Microinjector provides targeted delivery to potentially improve efficacy and compartmentalization of medication. Targeted drug delivery via the suprachoroidal space may also limit corticosteroid exposure to the anterior segment with the potential to reduce the risk of certain adverse events, such as cataracts, intraocular pressure elevation and exacerbation of glaucoma, that can commonly arise from other local corticosteroid delivery techniques..

Condition: Macular Oedema + Uveitis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.